Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Home About Us My Account Personal Library Customer Service    
Welcome Guest
(login/register)
US: 800.298.5699
Int'l: +1.240.747.3093
Quick Search
Advanced Search >
Research Assistance
Send us a request >
Latest Research by Email
Receive email alerts of new market research reports in your industry.
Sign Up Today >
Home > Back to Category > Report Information Email a colleague | Printer format

Commercial Insight: Asthma & Copd - Combination Products Still Have Blockbuster Potential

Datamonitor
July 11, 2007
269 Pages - Pub ID: DFMN1528844
 
Questions about this report >
Order by fax >
XE.com
Abstract

Table of
Contents
Related Reports


Introduction

Detailed analysis of the Asthma and COPD market. 10 year sales forecast for all major drugs brands in these indications, taking into account new treatment trends, clinical trial data, patent expirations and key new product launches in the 7 major markets.

Scope

Indication based forecasts for asthma/COPD products and significant pipeline drugs Assessment of country-specific drivers and resistors likely to impact the market Future market outlook for individual products taking into account key market events, in particular patent expiry and competitor launch dates Market overview by geographical area, with value analysis of clinical and commercial factors underlying product performance

Highlights

Asthma/COPD sales in the seven major markets are expected to grow to over $24 billion annually by 2010 and drop slightly thereafter due to patent expiries of key products. The ICS/LABA class is set to remain the leading class by value throughout, while the LAMA market will experience the strongest growth, particularly in COPD. A once-daily LABA/LAMA product should become the top-selling single brand in the seven major markets in 2016, depending on which company launches such a combination product first. However, combined sales of the Advair franchise (Advair/Seretide and once-daily Beyond Advair) will dominate the asthma/COPD market over the next ten years. The phase-out of CFC-containing inhalers in the US after 2008 will have a big impact on the market for short-acting beta2-agonists (SABAs), increasing this class' size significantly. The main beneficiary is expected to be IVAX's (now Teva) ProAir due to its favourable price compared with other marketed HFA SABAs.

Reasons to Purchase

Identify key opportunities and threats that will impact the use and uptake of new and existing products Quantify the future size and

Scope

of the asthma/COPD market and predict the future performance of key compounds Understand and capitalize on clinical unmet needs in the market, either through lifecycle management of marketed drugs or new product development

Please Note: This product is delivered as a zip file,which contains Excel and PDF files.

Related Reports:
Oxygen Therapy
Cancer Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report
Infections Tuberculosis Therapy Area Pipeline Report
Respiratory and Pulmonary System Asthma Therapy Area Pipeline Report
Respiratory and Pulmonary System Bronchitis Therapy Area Pipeline Report
Respiratory and Pulmonary System Bronchospasm Therapy Area Pipeline Report
Respiratory and Pulmonary System Chronic Obstructive Pulmonary Disease Therapy Area Pipeline Report
Respiratory and Pulmonary System Cough Therapy Area Pipeline Report
Respiratory and Pulmonary System Cystic Fibrosis Therapy Area Pipeline Report
Respiratory and Pulmonary System Nasal congestion Therapy Area Pipeline Report

Privacy Policy    |    Terms and Conditions    |    Site Map    |    Return Policy    |    Press    |    Help FAQs
Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/24/2009 - 4